8-K: Geron Corporation Announces Second Quarter 2024 Financial Results and RYTELO Commercial Launch Update

Geron Corporation reported its second quarter 2024 financial results, highlighted by the commercial launch of RYTELO and progress in clinical trials.

Summary

• Geron Corporation announced its second quarter 2024 financial results, which included the commercial launch of RYTELO in June 2024.
• The company reported a net loss of $67.4 million, or $0.10 per share, for the three months ended June 30, 2024, compared to a net loss of $49.2 million, or $0.09 per share, for the same period in 2023.
• Total product revenue for the quarter was approximately $780,000, driven by sales of RYTELO.
• Total net revenues for the quarter were $882,000, compared to $29,000 in the same period of 2023.
• Operating expenses for the quarter totaled $70.2 million, compared to $52.0 million in the same period of 2023.
• As of June 30, 2024, Geron had approximately $430.4 million in cash, cash equivalents, and marketable securities.
• The company estimates that approximately 160 patients have received RYTELO as of July 31, 2024.
• The NCCN Guidelines were updated to include RYTELO as a Category 1 and 2A treatment for symptomatic anemia in patients with lower-risk MDS.
• The Phase 3 IMpactMF trial of imetelstat has reached approximately 70% enrollment as of August 2024, with an interim analysis expected in early 2026 and final analysis in early 2027.
• Geron expects total operating expenses for fiscal year 2024 to be between $270 million and $280 million.
• The company believes its current cash and projected revenues will fund operations into the second quarter of 2026.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the successful commercial launch of RYTELO, inclusion in NCCN guidelines, and strong cash position. However, the increased net loss and operating expenses temper the overall sentiment.

Positives

• The commercial launch of RYTELO is underway and showing early signs of success with approximately 160 patients treated as of July 31, 2024.
• RYTELO has been included in the NCCN Guidelines as a Category 1 and 2A treatment, which should support adoption by physicians.
• The company has a strong cash position of $430.4 million as of June 30, 2024.
• The Phase 3 IMpactMF trial is progressing well with approximately 70% enrollment achieved.
• Total net revenues increased significantly to $882,000 for the quarter compared to $29,000 in the same period of 2023, driven by RYTELO sales.

Negatives

• Geron reported a net loss of $67.4 million for the second quarter of 2024, which is an increase from the $49.2 million loss in the same period of 2023.
• Operating expenses increased to $70.2 million for the quarter, up from $52.0 million in the same period of 2023.
• The company is still in the early stages of commercializing RYTELO, and it is not yet profitable.
• The company has $80 million in principal debt outstanding.

Risks

• The commercial success of RYTELO is not guaranteed and depends on market adoption and reimbursement.
• The company may face challenges in manufacturing and supplying sufficient quantities of RYTELO.
• The IMpactMF trial may not achieve its primary endpoint of overall survival.
• Regulatory authorities may not approve imetelstat for other indications.
• The company may need to raise additional capital to continue development and commercialization efforts.
• There are risks associated with the safety and efficacy of imetelstat, which could impact its approval and use.

Future Outlook

Geron expects total operating expenses for fiscal year 2024 to be in the range of approximately $270 million to $280 million and believes that its existing cash, cash equivalents, and marketable securities, together with projected revenues from U.S. sales of RYTELO, will be sufficient to fund its projected operating requirements into the second quarter of 2026.

Management Comments

• John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, stated that they are thrilled to have begun the launch of RYTELO and are encouraged by the early success and reception from the medical community.
• He also noted that their field teams have interacted with approximately 60% of their top decile 1-4 accounts and that approximately 160 patients have received RYTELO as of July 31, 2024.
• Management believes that RYTELO can become part of the standard-of-care for eligible patients with lower-risk MDS with transfusion-dependent anemia.

Industry Context

The announcement is significant as it marks Geron's transition to a commercial-stage company with the launch of RYTELO, a first-in-class telomerase inhibitor. The inclusion of RYTELO in the NCCN Guidelines is a positive development that could drive adoption by physicians. The company is competing in the hematology/oncology space, specifically targeting myelodysplastic syndromes and myelofibrosis, where there is a need for new treatment options.

Comparison to Industry Standards

• Geron's launch of RYTELO is a significant milestone, as it is the first telomerase inhibitor approved by the FDA for LR-MDS. This puts them in a unique position compared to companies offering traditional treatments like erythropoiesis-stimulating agents (ESAs).
• The reported 160 patients treated with RYTELO in the first six weeks of launch is a positive early indicator, but it is difficult to compare directly to other drug launches without more detailed sales data.
• The company's cash position of $430.4 million is relatively strong for a company of its size, providing a runway into Q2 2026, which is comparable to other biotech companies in the commercialization phase.
• The increase in operating expenses is expected given the commercial launch activities, and the company's guidance of $270-280 million for the year is within the range of other companies launching new drugs.
• The net loss of $67.4 million for the quarter is typical for a company in this stage, as they are investing heavily in commercialization and clinical trials. Companies like Karyopharm Therapeutics and Agios Pharmaceuticals, which have launched similar hematology/oncology drugs, have also reported significant losses during their launch phases.

Stakeholder Impact

• Shareholders: The commercial launch of RYTELO and positive clinical trial progress are positive for shareholders, but the increased net loss and operating expenses may be a concern.
• Employees: The company plans to increase its headcount, which is positive for employees.
• Customers: Patients with LR-MDS now have a new treatment option with RYTELO.
• Suppliers: The company's commercial launch will increase demand for manufacturing and distribution services.
• Creditors: The company's strong cash position and projected revenues provide some assurance to creditors.

Next Steps

• Continue the commercial launch of RYTELO in the U.S.
• Advance the Phase 3 IMpactMF trial of imetelstat.
• Expand the dose level 4 cohort in the Phase 1 IMproveMF study.
• Prepare for the interim analysis of the IMpactMF trial in early 2026.
• Continue to monitor and manage the safety profile of RYTELO.
• Grow the company's employee base to 230-260 by year-end 2024.

Key Dates

Keywords

RYTELO, imetelstat, myelodysplastic syndromes, MDS, myelofibrosis, commercial launch, NCCN Guidelines, clinical trial, IMpactMF, FDA approval, hematology, oncology, telomerase inhibitor